indiana fishing license
fortune gems free 100
fortune gems free 100
UBS starts coverage on gov service providers stock amid spending uncertaintyIn Aleppo, rebels give a sense of what may come in Syria
Art Basel Miami Beach 2024: Biggest parties and eventsNoneMGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells EMERYVILLE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a talk titled "Specific and efficient genome editing with metagenomics-derived tools for in vivo and ex vivo therapeutic applications” at the Nature Conference: RNA at the Bench and Bedside IV. "We believe the value proposition for single-dose gene editing therapies requires exquisite specificity characterization to ensure safety and efficacy. Today's presentation highlights the precision of Metagenomi's next-generation nucleases and ABEs, discovered through the company's proprietary metagenomics platform and tailored for both in vivo and ex vivo therapeutic applications,” said Alan Brooks, SVP and Head of Preclinical. "MGX-001, Metagenomi's development candidate for hemophilia A, which utilizes the novel nuclease MG29-1, exhibits no identifiable off-target editing using a series of orthogonal assays employed to evaluate potential off-target sites in the genome. The MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes. For Metagenomi's novel next-generation ABE for ex vivo cell therapy indications via multiplex editing, the data showed no detectable translocations and no significant genomic base composition differences in primary T-cells when compared to unedited cells. These examples demonstrate our strong capabilities in developing highly specific next-generation gene editing tools and support the company's ability to potentially progress these systems toward the clinic for the benefit of patients.” About Metagenomi Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases (CAST)). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co. Cautionary Note Regarding Forward‐Looking Statements This press release contains "forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as "anticipate,” "believe,” "could,” "estimate,” "expect,” "goal,” "intend,” "look forward to,” "may,” "plan,” "potential,” "predict,” "project,” "should,” "will,” "would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in "Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Contact: Simon Harnest - CIO, SVP Investor Relations IR@metagenomi.co
In-Depth Analysis Of The Monoethanolamine Market: Key Drivers, Trends, Growth Opportunities, And Forecast 2024-2033
Letters to the Editor | Tuesday, December 3, 2024Commentary: Australia’s under-16 social media ban - a flawed ultimatum to Big Tech is better than nothingFOXBOROUGH, Mass. (AP) — The New England Patriots are focused on the future following their 25-24 loss to the Indianapolis Colts . The Patriots (3-10) were officially eliminated from playoff contention with the loss Sunday, meaning that this week’s bye in many ways will begin the process of the coaching staff and front office evaluating the roster for 2025. The good news is that this group has shown plenty of grit this season, playing seven games that were decided by one score. The bad news is that the Patriots are just 2-5 in those games. Though New England’s bye comes late in the season, coach Jerod Mayo said the timing is perfect for a team that is feeling the effects of its shortcomings . “A much-needed bye week, not only physically for the players but also mentally, just being able to hit the reset button and come back, put some good games together and continue to build for the future,” Mayo said. “That has to be our goal.” Tight end Austin Hooper said the seed that needs to be planted over the final four games is finding a way to limit the mistakes — namely penalties and trouble finishing drives — that have hampered the offense throughout the season. “We’ve got to execute at a higher level. We can’t beat a team before you stop hurting yourself,” Hooper said. “It’s not for lack of effort, just things that happen out there that get you scars in this league.” This was the most balanced performance by the offense this season, with 222 passing yards and a season-high 200 yards rushing. It shows progress under new coordinator Alex Van Pelt, which is something to build on over the final four games. Red zone efficiency. It continues to be the most glaring deficiency for the Patriots’ offense. They were 2 of 6 on Sunday and rank 30th in the NFL, scoring a touchdown only 44.7% (17 of 38) of the time inside the 20-yard line. TE Hunter Henry. He finished with seven catches for 75 yards, which is his seventh game this season with five or more receptions. He leads the team this season with 58 catches for 610 yards and continues to be a dependable option for quarterback Drake May as he navigates his rookie season. K Joey Slye. He made 3 of his 5 field-goal attempts, including a 54-yarder in the second quarter. Most of the conversation following the game was about his NFL record-long 68-yard attempt that came up short as time expired. But because of the 1-point loss, he was lamenting the 25-yard attempt he missed wide left just before halftime. “I take full responsibility for this,” Slye said. “Every point for this team matters with how we play complementary football with offense, defense and special teams. So, whenever I am out there, I have got to score points.” Henry left the game in the first quarter after a helmet-to-helmet hit. He was able to return in the second quarter and finished the game. 7 — Number of penalties called on the Patriots, costing them 88 yards. Five penalties (four accepted) were called on the offensive line. That included one for holding on Mike Onwenu that nullified a touchdown run by Rhamondre Stevenson in the first quarter and forced New England to settle for a field goal. The Patriots have a bye this week. They visit the Arizona Cardinals on Dec. 15. AP NFL coverage: https://apnews.com/hub/NFL
NoneSome Democrats are frustrated over Joe Biden reversing course and pardoning his son Hunter
None
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on December 2, 2024, the Compensation Committee of Zentalis' Board of Directors granted the following equity awards: non-qualified stock options to purchase an aggregate of 3,028,800 shares of the Company's common stock to Julie Eastland, who joined the Company as Chief Executive Officer and President, non-qualified stock options to purchase an aggregate of 712,650 shares of the Company's common stock to Dr. Ingmar Bruns, who joined the Company as Chief Medical Officer, and non-qualified stock options to purchase an aggregate of 753,660 shares of the Company's common stock to five newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $3.66 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options granted to Ms. Eastland have a 10-year term and will vest over four years in equal monthly installments until the stock options are fully vested. The stock options granted to the other newly hired employees have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employee's continued service to Zentalis on each vesting date. About Zentalis Pharmaceuticals Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company's lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors. Azenosertib is being evaluated as a monotherapy and in combination across multiple clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. As part of its azenosertib clinical development program, the Company is exploring enrichment strategies targeting tumors of high genomic instability, such as Cyclin E1 positive tumors, homologous recombination deficient tumors and tumors with oncogenic driver mutations. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in San Diego. For more information, please visit www.zentalis.com . Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals . ZENTALIS ® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release. Contacts: Elizabeth Hickin Vice President, Investor Relations [email protected]
By Tom Hals and Jonathan Stempel WILMINGTON, Delaware (Reuters) - A Delaware judge ruled on Monday that Tesla CEO Elon Musk still is not entitled to receive a $56 billion compensation package despite shareholders of the electric vehicle company voting in June to reinstate it. The ruling by the judge, Chancellor Kathaleen McCormick of the Court of Chancery, follows her January decision that called the pay package excessive and rescinded it, surprising investors, and cast uncertainty over Musk's future at the world's most valuable carmaker. Musk did not immediately respond to an emailed request for comment. Tesla in a statement on X said, "The ruling is wrong, and we're going to appeal," saying that the judge had overruled a supermajority of shareholders. Musk and Tesla can appeal to the Delaware Supreme Court as soon as McCormick enters a final order, which could come as soon as this week. The appeal could take a year to play out. Tesla has said in court filings that the judge should recognize a subsequent June vote by its shareholders in favor of the pay package for Musk, the company's driving force who is responsible for many of its advances, and reinstate his compensation. McCormick said Tesla’s board was not entitled to hit “reset” to restore Musk’s pay package. “Were the court to condone the practice of allowing defeated parties to create new facts for the purpose of revising judgments, lawsuits would become interminable,” she said in her 101-page opinion. She said a ratification vote like the one used by Tesla had to be conducted before the trial and a company cannot ratify a transaction involving a conflicted controller. She had determined Musk controlled the pay negotiations. She also said Tesla made multiple material misstatements in its proxy statement regarding the vote, and could not claim the vote was a “cure-all” to justify restoring Musk’s pay. Tesla shares fell 1.4% in after hours trade, after the ruling. Gary Black, managing partner of The Future Fund, which owns Tesla stock, said on X that he believed the Delaware Supreme Court was more pragmatic than McCormick. "I doubt this ruling will be resolved anytime soon, and it will likely be overturned by a more moderate court along the way," he wrote. The pay package had awarded Musk stock options if the company hit performance and valuation goals. While the award originally was valued at up to $56 billion, Tesla's shares have surged 42% since Nov. 5, when Republican candidate Donald Trump, supported by Musk, won the U.S. presidential election. Following that rally, the pay package is worth about $101 billion. The ruling comes as Musk has been tasked by Trump with creating a more efficient government by slashing spending. The role as co-lead of the new Department of Government Efficiency would be informal rather than a government position, allowing Musk to keep his job at Tesla as well as leading other companies including rocket maker SpaceX. Musk threw himself behind Trump's election campaign and has become a close adviser in the process. PAY DAY FOR PLAINTIFF'S LAWYERS McCormick also ordered Tesla to pay the attorneys who brought the case $345 million, well short of the $6 billion they initially requested, but still one of the largest fee awards ever in securities litigation. She said the fee could be paid in cash or Tesla stock. “We are pleased with Chancellor McCormick’s ruling, which declined Tesla’s invitation to inject continued uncertainty into Court proceedings," said a statement from Bernstein Litowitz Berger & Grossmann, one of the three law firms for the plaintiff. The law firm also said it looked forward to defending the court's opinion if Musk and Tesla appealed. After the January ruling, Tesla shareholders flooded the court with thousands of letters arguing that rescinding Musk's pay increased the possibility he would leave Tesla or develop some products like artificial intelligence at ventures other than Tesla. Mom-and-pop investors and Musk's influential fans helped Tesla and Musk win the June shareholder vote and many were speaking up on social media against Monday's decision. "Beyond the pedantic details of legal procedure, the bigger issue here is that the voice of shareholders is being overruled," Omar Qazi said in a post on X from the handle @WholeMarsBlog after Monday's ruling. "If they can't consider the vote in this case, hopefully they'll consider it on appeal," said Qazi who has more than 551,000 followers. McCormick in January found that Musk improperly controlled the 2018 board process to negotiate the pay package. The board had said that Musk deserved the package because he hit all the ambitious targets on market value, revenue and profitability. After the January ruling, Musk criticized the judge on his social media platform X and encouraged other companies to follow the lead of Tesla and reincorporate in Texas from Delaware, although it is unclear if any companies did so. The judge in her January ruling called the pay package the "biggest compensation plan ever - an unfathomable sum." It was 33 times larger than the next biggest executive compensation package, which was Musk's 2012 pay plan. Musk's 2018 pay package gave him stock grants worth around 1% of Tesla's equity each time the company achieved one of 12 tranches of escalating operational and financial goals. Musk did not receive any guaranteed salary. Tornetta argued that shareholders were not told how easily the goals would be achieved when they voted on the package. (Reporting by Tom Hals in Wilmington, Delaware; additional reporting by Abhirup Roy and Noel Randewich in San Francisco; Editing by Bill Berkrot, Amy Stevens, Peter Henderson and Sonali Paul)Responding to a significant increase in potential threats to lawmakers and the public in recent years, Secretary of State Alexi Giannoulias’s office recently implemented new emergency rules requiring nearly anyone to pass through security screening upon entering the Statehouse or any building in the Illinois Capitol Complex. “Unfortunately, the world is not getting safer,” Amy Williams, senior legal adviser in the secretary of state’s office, told a legislative oversight committee Tuesday. One of the more serious threats, Williams said, occurred in March when security officials were notified of an active shooter threat, prompting a lockdown of the complex. The lockdown was lifted after investigators determined there was no credible threat, according to reports at the time. In April, police locked down the Capitol for about an hour as the building was cleared following a bomb threat. Illinois State Police arrested a suspect accused of making the threat the following month. So far in 2024, Williams told the committee, the Secretary of State Police Department has responded to 17 threats to the Capitol, nearly twice as many as any other year since 2018. There have also been threats directed at individual lawmakers. In September, a man was arrested for threatening to assassinate Rep. Jeff Keicher, R-Sycamore. And on Monday, Dec. 9, Rep. Barbara Hernandez, D-Aurora, reported an employee in her district office became ill after opening office mail, according to a social media post. The employee was transported to a local hospital, prompting police to evacuate the building and cordon off a portion of the street while emergency crews responded. In October, Williams said, the secretary of state’s office was advised by a security consultant to increase the number of people required to go through security screening to include everyone other than lawmakers, state government employees and other elected officials. That meant many people who had previously been given unrestricted access to the building — including lobbyists, vendors and members of the news media — now have to go through security screening as well. “Primarily that decision came about because members of the General Assembly, elected officials, are sensibly background checked by their constituents who choose them to go to the Capitol to do the people's work on their behalf,” she said. “And state government employees are background checked by their respective agencies. Lobbyists, vendors and members of the press are not subject to any background check.” To avoid congestion, Williams said the office has set up a “TSA Express-style” screening point at the east entrance of the building for those individuals who previously had unfettered access. The security changes near the tail end of a three-year, $224 million renovation project that will make permanent changes to the way the public enters and exits the Capitol. That project involves restoration and remodeling of the entire north wing of the Capitol. When it’s completed, sometime in 2025, all public access will be through a new entryway on the north side of the building where people will pass through security screening before entering the building itself. Until then, visitors will continue entering through either the east or west doors of the building where metal detectors and baggage x-ray machines are located just inside the building. Lawmakers are tentatively scheduled to return to the Statehouse Jan. 2 for the start of a brief lame duck session. The regular 2025 session begins Wednesday, Jan. 8.ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: 7th Annual Evercore HealthCONx (Coral Gables, FL). MacroGenics’ President and Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30am ET. MacroGenics’ management will also participate in one-on-one meetings. A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm . The Company will maintain an archived replay of this webcast on its website for 30 days. About MacroGenics, Inc. MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com . MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc. ### CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
NoneNEW YORK (AP) — U.S. stock indexes got back to climbing on Wednesday after the latest update on inflation appeared to clear the way for more help for the economy from the Federal Reserve. The S&P 500 rose 0.8% to break its first two-day losing streak in nearly a month and finished just short of its all-time high. Big Tech stocks led the way, which drove the Nasdaq composite up 1.8% to top the 20,000 level for the first time. The Dow Jones Industrial Average, meanwhile, lagged the market with a dip of 99 points, or 0.2%. Stocks got a boost as expectations built that Wednesday's inflation data will allow the Fed to deliver another cut to interest rates at its meeting next week. Traders are betting on a nearly 99% probability of that, according to data from CME Group, up from 89% a day before. If they're correct, it would be a third straight cut by the Fed after it began lowering rates in September from a two-decade high. It's hoping to support a slowing job market after getting inflation nearly all the way down to its 2% target. Lower rates would give a boost to the economy and to prices for investments, but they could also provide more fuel for inflation. "The data have given the Fed the 'all clear' for next week, and today's inflation data keep a January cut in active discussion," according to Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management. Expectations for a series of cuts to rates by the Fed have been one of the main reasons the S&P 500 has set an all-time high 57 times this year, with the latest coming last week. The biggest boosts for the index on Wednesday came from Nvidia and other Big Tech stocks. Their massive growth has made them Wall Street's biggest stars for years, though other kinds of stocks have recently been catching up somewhat amid hopes for the broader U.S. economy. Tesla jumped 5.9% to finish above $420 at $424.77. It's a level that Elon Musk made famous in a 2018 tweet when he said he had secured funding to take Tesla private at $420 per share. Stitch Fix soared 44.3% after the company that sends clothes to your door reported a smaller loss for the latest quarter than analysts expected. It also gave financial forecasts for the current quarter that were better than expected, including for revenue. GE Vernova rallied 5% for one of the biggest gains in the S&P 500. The energy company that spun out of General Electric said it would pay a 25 cent dividend every three months, and it approved a plan to send up to another $6 billion to its shareholders by buying back its own stock. On the losing end of Wall Street, Dave & Buster's Entertainment tumbled 20.1% after reporting a worse loss for the latest quarter than expected. It also said CEO Chris Morris has resigned, and the board has been working with an executive-search firm for the last few months to find its next permanent leader. Albertsons fell 1.5% after filing a lawsuit against Kroger, saying it didn't do enough for their proposed $24.6 billion merger agreement to win regulatory clearance. Albertsons said it's seeking billions of dollars in damages from Kroger, whose stock rose 1%. A day earlier, judges in separate cases in Oregon and Washington nixed the supermarket giants' merger. The grocers contended a combination could have helped them compete with big retailers like Walmart, Costco and Amazon, but critics said it would hurt competition. After terminating the merger agreement with Kroger, Albertsons said it plans to boost its dividend 25% and increased the size of its program to buy back its own stock. Macy's slipped 0.8% after cutting some of its financial forecasts for the full year of 2024, including for how much profit it expects to make off each $1 of revenue. All told, the S&P 500 rose 49.28 points to 6,084.19. The Dow dipped 99.27 to 44,148.56, and the Nasdaq composite rallied 347.65 to 20,034.89. In the bond market, the yield on the 10-year Treasury rose to 4.27% from 4.23% late Tuesday. The two-year Treasury yield, which more closely tracks expectations for the Fed, edged up to 4.15% from 4.14%. In stock markets abroad, indexes rose across much of Europe and Asia. Hong Kong's Hang Seng was an outlier and slipped 0.8% as Chinese leaders convened an annual planning meeting in Beijing that is expected to set economic policies and growth targets for the coming year. South Korea's Kospi rose 1%, up for a second straight day as it climbs back following last week's political turmoil where its president briefly declared martial law.LOS ANGELES (AP) — Southern California quarterback Miller Moss is entering the transfer portal after losing the Trojans' starting job last month. Moss made his announcement on social media Monday. Moss started the Trojans ' bowl victory last season and their first nine games this season before coach Lincoln Riley replaced him with Jayden Maiava in early November. “Being a USC Trojan was a lifelong dream of mine,” Moss wrote. “Putting on the cardinal and gold and competing on behalf of my teammates and school is something I will forever take pride in. I poured everything I have into this — body, heart, mind and soul — and am humbled by and proud of what my teammates and I accomplished.” Moss, who was born in Los Angeles and went to high school in the San Fernando Valley, signed with USC before Riley arrived at the school. Moss also stayed with the Trojans after Caleb Williams transferred from Oklahoma to rejoin Riley, and he served as Williams’ backup for two seasons before getting his chance to play with six touchdown passes in last year's Holiday Bowl. Moss completed 64.4% of his passes this season for 2,555 yards with 18 touchdowns and nine interceptions. After a spectacular 378-yard performance to beat LSU in the Trojans' season opener, Moss didn't play poorly as a starter, but he also wasn't a difference-maker while USC stumbled to a 4-5 record. Moss threw seven interceptions in his final five starts before losing the job to Maiava. The Trojans went 1-4 in that stretch under Moss, who plays as a more traditional pocket passer while Maiava has the mobility usually favored for quarterbacks in Riley's spread offense. “Looking towards the future, I'm unwaveringly committed to becoming an even better quarterback and leader, and to achieving this at the next level,” Moss wrote. Moss has already graduated from USC, putting him in the portal as a graduate student. USC (6-6) is headed to a lower-tier bowl game again to finish this season, its third under Riley. AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
- Previous:
- Next: fortune gems free demo